Faruqi & Faruqi Reminds Boston Scientific Investors of Securities Class Action Deadline

Law firm encourages investors who suffered losses to contact them directly to discuss options

Mar. 21, 2026 at 11:35am

Got story updates? Submit your updates here. ›

Faruqi & Faruqi, LLP, a national securities law firm, is investigating potential claims against Boston Scientific Corporation and reminds investors of the May 4, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the company. The complaint alleges that Boston Scientific and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose the true state of the company's U.S. EP segment, including that management was aware the segment's growth rate was unsustainable.

Why it matters

This case highlights concerns about Boston Scientific's transparency with investors regarding the performance of its key business segments. The lawsuit alleges the company misled investors about the challenges facing its U.S. EP segment, leading to a significant stock price drop when the true state of the business was revealed.

The details

On February 4, 2026, Boston Scientific published disappointing Q4 2025 results and fiscal 2026 guidance, citing slower than expected market growth and increased competition in its U.S. EP segment, despite previous claims of a 'growing' business. This news caused Boston Scientific's stock price to fall 17.6% in a single day.

  • The class period covers July 23, 2025 to February 3, 2026.
  • The deadline for investors to seek lead plaintiff status is May 4, 2026.

The players

Boston Scientific Corporation

A medical device company that develops, manufactures and markets a range of implantable devices, including those used in cardiac rhythm management, interventional cardiology and neuromodulation.

Faruqi & Faruqi, LLP

A leading national securities law firm that has recovered hundreds of millions of dollars for investors since its founding in 1995.

James (Josh) Wilson

A securities litigation partner at Faruqi & Faruqi who is encouraging investors who suffered losses to contact him directly.

Got photos? Submit your photos here. ›

What they’re saying

“If you purchased or acquired securities in Boston Scientific between July 23, 2025 and February 3, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).”

— James (Josh) Wilson, Securities Litigation Partner, Faruqi & Faruqi, LLP

What’s next

The court will appoint a lead plaintiff, who will oversee the litigation on behalf of the putative class. Investors have until May 4, 2026 to seek lead plaintiff status.

The takeaway

This lawsuit highlights the importance of transparency and accurate disclosures by public companies. Investors who suffered losses due to Boston Scientific's alleged misrepresentations may be able to recover damages through the class action lawsuit.